Core Insights - NLS Pharmaceutics Ltd. has submitted three research abstracts to the 2025 Annual Meeting of the American Society of Clinical Psychopharmacology, focusing on innovative therapies for CNS disorders [1][5] Group 1: Research Abstracts - The first study evaluates the effects of Mazindol ER on fentanyl dependence, demonstrating its potential as a non-opioid alternative for managing addiction [8] - The second study presents preclinical findings on AEX-41 and AEX-2, two novel dual orexin receptor agonists, showing their wake-promoting properties in a mouse model of narcolepsy [4][8] - The third study introduces a comprehensive multitarget strategy for managing diabetes-associated neurological and sleep disorders, integrating various therapeutic approaches [4] Group 2: Event Details - The ASCP Annual Meeting will take place from May 27 to May 30, 2025, in Scottsdale, Arizona, serving as a key platform for advancements in neuropsychopharmacology [2] - This event is recognized globally for its focus on neuropsychiatric drug development and innovative therapeutic approaches [2] Group 3: Company Overview - NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex CNS disorders, collaborating with leading scientists and pharmaceutical partners [6]
NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting